MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)

NCT04358913 | Recruiting DMC

• 1 other identifier: IIT-0013
• Study Type: interventional
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, breast, gynecological, pancreas, and head and neck)

  Clinical radiologists, medical physicists, and radiation oncologists will work together to develop MR sequences that can delineate tumour target volumes on the Alberta linac-MR P3 system. Over the course of the trial, the clinical radiologists will work with medical physicists to optimize these sequences to allow for the development of optimal MR images, with the goal to develop of series of protocols that can be utilized to provide clear MR image guidance for each tumour group.

  Through study completion, approximately 7 years

Secondary Outcomes (1)

• Quantify the patient experience on the Linac-MR

  After the first and last scan, up to 5 weeks

Study Arms (1)

MR Imaging on the Alberta linac-MR P3 system

EXPERIMENTAL

All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.

Device: MR scan with the Alberta linac-MR P3 system

Interventions

MR scan with the Alberta linac-MR P3 system DEVICE

Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.

MR Imaging on the Alberta linac-MR P3 system

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults ≥ 18 years of age
• Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist

You may not qualify if:

• Patients with contraindications for MRI
• Patients who are unable to lie flat and still for the duration of the expected scan acquisition
• Patients who are unable to provide informed consent

Sponsors & Collaborators

• AHS Cancer Control Alberta: lead

Study Sites (1)

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

• Nawaid Usmani, MD

  Cross Cancer Institute, Alberta Health Services

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nawaid Usmani, MD

CONTACT

780-432-8518; Nawaid.Usmani@ahs.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2020
• First Posted: April 24, 2020
• Study Start: August 23, 2021
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): January 1, 2029
• Last Updated: May 14, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)